Blood-Brain Barrier Protein Imbalance Mapped Across 2,171 Aging Brains

The brain is physically separated from the bloodstream by a sophisticated barrier system—including the blood-brain barrier, choroid plexus, and meningeal vasculature—that tightly regulates which molecules enter or exit the central nervous system. Disruption of this system is implicated in aging and neurodegeneration, yet large-scale proteomic characterization of how the CSF-plasma protein balance changes has been lacking.

In this study, the research team leveraged SomaScan aptamer-based proteomics to profile paired CSF and plasma samples from 2,171 healthy or cognitively impaired older individuals across multiple cohorts, including the newly established Global Neurodegeneration Proteomics Consortium (GNPC). Participants spanned a spectrum from cognitively normal to mild cognitive impairment and Alzheimer's disease. The primary metric was the CSF-to-plasma protein ratio, which serves as a proxy for barrier permeability and active transport.

A key finding was that CSF-to-plasma ratios of 848 proteins increased with normal aging, enriched for complement and coagulation cascade proteins, chemokines, and proteins previously linked to neurodegeneration. By contrast, only 64 protein ratios decreased with age, indicating that the barrier becomes more permissive with aging in a substrate-specific manner rather than simply 'leaking' uniformly. Proteins with correlated CSF and plasma levels were identified as primarily peripherally produced and enriched for structural domains—such as collagen-like motifs—potentially enabling active transcytosis across brain barriers.

Strikingly, higher CSF-to-plasma ratios of several peripherally derived or vascular-associated proteins—including DCUN1D1, MFGE8, and VEGFA—were associated with preserved cognitive function, suggesting that certain peripheral signals entering the CSF may be neuroprotective or reflect a healthier barrier state. Genome-wide association studies (GWAS) identified genetic loci controlling CSF-to-plasma ratios of 241 proteins; many map to known disease-associated regions. FCN2 (Ficolin-2), whose collagen-like domain appears to facilitate transport across the blood-CSF interface, was a notable hit.

The study's broad implications span basic neuroscience, biomarker discovery, and drug development. Understanding which structural features allow proteins to cross into the CSF could inform the engineering of CNS-targeted biologics. The identification of genetically regulated protein ratios also opens new avenues for Mendelian randomization studies to test causal relationships between specific proteins and neurodegeneration. Limitations include the cross-sectional design for most cohorts, the use of aptamer-based rather than mass-spectrometry proteomics (with potential off-target binding), and the predominance of older European-ancestry participants, which may limit generalizability.